Johnson & Johnson Diabetes Institute To Provide Education, Training to Health Professionals
With mounting evidence that many health professionals lack the training and skills to combat the nation's growing epidemic of diabetes, the Johnson & Johnson Diabetes Institute, LLC opened its first training center in the U.S. to improve how practitioners deliver diabetes care in local communities.
Read more ...
ANAVEX outlines corporate milestones, drug advancement plans for 2008
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) reported that the company achieved significant development of its lead drug candidates and in the growth of its management and scientific teams during 2007. The company further disclosed key corporate objectives for 2008.
Read more ...
Collexis Holdings, Inc. Acquires SyynX Solutions GmbH, Expands Application Portfolio
Collexis Holdings, Inc. (OTCBB: CLXS) has acquired its long-time development partner, SyynX Solutions, a privately-held software company based in Cologne, Germany. SyynX Solutions will remain as a subsidiary of Collexis Holdings â with the amendment "a Collexis company", and will take care of existing customers and drive Collexis' business in Europe.
Read more ...
CIBA Vision announces settlement of patent litigation with CooperVision, Inc.
CIBA Vision, the eye care unit of Novartis, has reached a final global patent litigation settlement agreement with CooperVision, Inc. (NYSE: COO) that resolves all current patent infringement lawsuits between the two companies. CIBA Vision has licensed its so called "Nicolson" patents to CooperVision. This will enable both companies to move forward in bringing forth new and improved innovations to meet the needs of eye care professionals and consumers.
Read more ...
Bionas Signs Service Contract with Solvay Pharmaceuticals
Bionas GmbH, a specialist for in vitro profiling of cellular metabolic activity, announced that it has signed a service contract with Solvay Pharmaceuticals GmbH (Hannover, Germany). The contract covers the metabolic profiling of several drug candidates identified in the context of Solvay's obesity research program. Financial details were not disclosed.
Read more ...
Protherics signs ReGel⢠licensing agreement with Myungmoon Pharm
Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announces that it has signed a licensing agreement with Myungmoon Pharm. Co. Ltd., a Korean pharmaceutical company, granting it the rights to develop anti-inflammatory products using Protherics' local, sustained release drug delivery system ReGel™.
Read more ...
Teva Receives Positive Feedback on Second AOK Tender in Germany
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced that it has received notification from Allgemeinen Ortskrankenkassen (AOK), Germany's largest health insurance company, on the results of the most recent tender for finished dosage pharmaceutical products. Teva is very pleased to have been awarded a significant increase in the number of molecules for which it can contract to supply during 2008-2009; compared to the six products it was awarded in the first tender earlier this year.
Read more ...